EMA's Medical Literature Monitoring Service Creates New Complexities For Pharma
This article was originally published in SRA
Executive Summary
Several drug companies are struggling to align their processes with the European Medicines Agency's new medical literature monitoring (MLM) service that was launched earlier this year to reduce the administrative burden associated with monitoring and reporting of suspected adverse reactions from drugs containing certain active substances1,2.